| P/E (FY) | — | Sales (TTM) | €4.1M |
| Earnings (TTM) | -€5.5M | ROE | −92.29% |
| Net Margin | −136.60% | ROIC | — |
| Debt / Equity | 0.54 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −8.20% |
ABIONYX Pharma SA is a biotech company that researches and develops therapies for renal, metabolic, and ophthalmic diseases in France and the United States. It operates through drug-development and contract research organization segments. Its lead candidate, CER-001, is a recombinant HDL mimetic in Phase III for LCAT deficiency and Phase II for sepsis, while ABNX-100 is in preclinical testing for uveitis. The company was formerly Cerenis Therapeutics Holding SA.
| Market Cap | $76.2M | Trading Days | 2841 |
| 52W High | 5.29 |
| 52W Low | 1.36 |
| % Off High | −63.78% |
| YTD | −49.38% | 1Y | 23.61% |
| 3Y | 57.83% | 5Y | 71.07% |
| 10Y | −72.67% | Since incept. (ann.) | −15.15% |
| Ann. Volatility (1Y) | 94.33% | Ann. Volatility (3Y) | 67.04% |
| Sharpe (1Y) | 0.65 | Sharpe (3Y) | 0.55 |
| Max Drawdown (1Y) | −63.16% | Max Drawdown (3Y) | −63.16% |
| Beta (3Y, vs SPY) | 0.18 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SPAI | Safe Pro Group Inc. | $76.5M | — |
| JUSHF | Jushi Holdings Inc. | $75.9M | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $75.9M | 16.5 |
| GNPX | Genprex, Inc. | $75.4M | — |
| ACET | Adicet Bio, Inc. | $77.6M | — |
| NRXS | Neuraxis, INC | $74.8M | — |
| BTMD | biote Corp. | $74.8M | 2.8 |
| GANX | Gain Therapeutics, Inc. | $73.8M | — |
| XAIR | Beyond Air, Inc. | $79.4M | — |
| MAIA | MAIA Biotechnology, Inc. | $73.0M | — |
| HYPR | Hyperfine, Inc. | $72.9M | — |
| PARK |
| Park Dental Partners, Inc. |
| $79.7M |
| — |
